- After almost 17 years in the position
- Praise, thanks and good wishes for Gorman
- Kyle Gano taking over
- Gorman made a lengthy statement and said 214 words
(exechange) — San Diego, California, May 28, 2024 — This news came shortly after Memorial Day. Kevin Gorman, chief executive of Neurocrine, leaves his position. As announced by Neurocrine Biosciences Inc. in a news release and in a regulatory filing published on Tuesday, May 28, 2024, Kevin C. Gorman leaves his post as chief executive officer at the biopharmaceutical company, after almost 17 years in the role, effective October 11, 2024.
It is the end of an era.
Kevin Gorman’s duties as CEO will be taken over by Kyle Gano, currently Chief Business Development and Strategy Officer at Neurocrine Biosciences Inc.
“Well-planned leadership transition”
The planned management change is explained as follows. Gorman stated: “With the foundation of a world-class team, compelling science, and clear vision, it is the right time to initiate this well-planned leadership transition.”
Precise information regarding Kevin Gorman’s future plans was not immediately available.
“Retire”
Neurocrine said: “Kevin Gorman, Ph.D., will retire as Chief Executive Officer of Neurocrine on October 11, 2024.”
Share price increase since May 2019
The announcement follows an increase in Neurocrine Biosciences Inc.’s share price of 87% since May 2019.
In the position of CEO since 2008
Kevin Gorman became CEO of the Company in 2008.
Kevin C. Gorman, Ph.D. has been employed with the Company since 1993.
He was appointed President and Chief Executive Officer in January 2008 after having served as Executive Vice President and Chief Operating Officer since September 2006 and prior to that, as Executive Vice President and Chief Business Officer and Senior Vice President of Business Development.
He currently serves as Chief Executive Officer and has served on the Board of Directors since January 2008. Gorman currently serves as a director of Xencor, Inc. a publicly traded clinical-stage biopharmaceutical company. Additionally, he serves on the Board of Directors of the Biotechnology Innovation Organization (BIO) and the Pharmaceutical Research and Manufacturers of America (PhRMA).
From 1990 until 1993, Gorman was a principal of Avalon Medical Partners, L.P. where he was responsible for the early stage founding of the company and several other biotechnology companies such as Onyx Pharmaceuticals, Inc., Metra Biosystems, Inc., Idun Pharmaceuticals, Inc. and ARIAD Pharmaceuticals, Inc.
Gorman received his Ph.D. in immunology and M.B.A. in Finance from the University of California, Los Angeles and did further post-doctoral training at The Rockefeller University.
214 words by Kevin Gorman
In the release announcing his departure as CEO of Neurocrine Biosciences Inc., Kevin Gorman received praise, thanks and good wishes.
In the release announcing his departure as CEO, Kevin Gorman made a lengthy statement and said 214 words.
“I couldn’t be prouder”
Kevin Gorman stated: “It has been a privilege to lead the Neurocrine team in developing life-changing treatments for patients in need. When I took on the role of CEO in 2008, Neurocrine was a clinical stage company with a limited pipeline and no approved products. Together, we have built a diverse pipeline and a leading R&D innovation engine designed to rapidly deliver up to four INDs per year. We successfully launched INGREZZA, which has driven strong financial results while improving the treatment of tardive dyskinesia and chorea associated with Huntington’s disease. Importantly, we are working diligently to be prepared to bring crinecerfont to patients with CAH next year, if approved. I couldn’t be prouder of all that this team has accomplished, and I have never been more confident in Neurocrine’s future. With the foundation of a world-class team, compelling science, and clear vision, it is the right time to initiate this well-planned leadership transition. The Board of Directors is confident Kyle is the ideal CEO to lead Neurocrine’s next chapter of growth, as am I. We have worked closely together for more than 20 years. He has been instrumental in Neurocrine’s success and is an exceptional leader of the organization. I look forward to supporting him in my continuing role as a member of the Neurocrine Board.”
The above text is an excerpt from the exechange report 23.2024 ($), publication date June 3, 2024.